Skip to Content Facebook Feature Image

KB Home Announces the Grand Opening of Chapel Manor, Its Newest Community in Zephyrhills, Florida

Business

KB Home Announces the Grand Opening of Chapel Manor, Its Newest Community in Zephyrhills, Florida
Business

Business

KB Home Announces the Grand Opening of Chapel Manor, Its Newest Community in Zephyrhills, Florida

2025-11-17 20:59 Last Updated At:11-18 13:30

TAMPA, Fla.--(BUSINESS WIRE)--Nov 17, 2025--

KB Home (NYSE: KBH), one of the largest and most trusted homebuilders in the U.S., today announced the grand opening of Chapel Manor, a new-home community in Zephyrhills, Florida. These new homes are designed for the way people live today, with popular features like modern kitchens overlooking large great rooms, expansive bedroom suites with walk-in closets, and lofts. The community’s one- and two-story floor plans feature up to six bedrooms and three-and-a-half baths. Chapel Manor is zoned for Pasco County Schools, with New River Elementary, Centennial Middle and Zephyrhills High Schools all within three miles of the community. Additionally, Chapel Manor has no CDD fees.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117638507/en/

What sets KB Home apart is the company’s focus on building strong, personal relationships with every customer, so they have a real partner in the homebuying process. Every KB home is uniquely built for each customer, so no two KB homes are the same. Homebuyers have the ability to personalize their new home, from floor plans to exterior styles to where they live in the community. Their home comes to life in the KB Home Design Studio, a one-of-a-kind experience where customers get both expert advice and the opportunity to select from a wide range of design choices that fit their style and their budget. Reflecting the company's commitment to creating an exceptional homebuying experience, KB Home is the #1 customer-ranked national homebuilder in Tampa based on homebuyer satisfaction surveys from a leading third-party review site.

“We are pleased to offer area homebuyers new one- and two-story homes in a great location close to schools and a variety of outdoor recreation,” said Douglas Guy, President of KB Home’s Tampa division. “Families will also appreciate Chapel Manor’s proximity to shopping and dining at KRATE, The Grove at Wesley Chapel, The Shops at Wiregrass and Tampa Premium Outlets ®. At KB Home, we’re here to help you achieve your dream with a personalized new home built uniquely for you and your life.”

Innovative design plays an essential role in every home KB builds. The company’s floor plans inspire contemporary living, with a focus on roomy, light-filled spaces that have easy indoor/outdoor flow. KB homes are engineered to be highly energy and water efficient and include features that support healthier indoor environments. They are also designed to be ENERGY STAR ® certified — a standard that fewer than 12% of new homes nationwide meet — offering greater comfort, well-being and utility cost savings than new homes without certification.

Chapel Manor is in a convenient location that offers homebuyers an exceptional lifestyle. The new community is situated at the corner of Handcart Road and Fairview Heights Road, which provides easy access to Interstate 75. Chapel Manor is just minutes from a variety of outdoor recreation, including family friendly parks, hiking trails and Crystal Springs Preserve. The community is also close to several golf courses, including Tampa Bay Golf and Country Club and Lake Jovita Golf & Country Club.

The Chapel Manor sales office and model homes are open for walk-in visits and private in-person tours by appointment. Homebuyers also have the flexibility to arrange a live video tour with a sales counselor. Pricing begins from the high $200,000s.

For more information on KB Home, call 888-KB-HOMES or visit kbhome.com.

About KB Home

KB Home is one of the largest and most trusted homebuilders in the United States. We operate in 49 markets, have built nearly 700,000 quality homes in our more than 65-year history, and are honored to be the #1 customer-ranked national homebuilder based on third-party buyer surveys. What sets KB Home apart is building strong, personal relationships with every customer and creating an exceptional experience that offers our homebuyers the ability to personalize their home based on what they value at a price they can afford. As the industry leader in sustainability, KB Home has achieved one of the highest residential energy-efficiency ratings and delivered more ENERGY STAR® certified homes than any other builder, helping to lower the total cost of homeownership. For more information, visit kbhome.com

KB Home announces the grand opening of Chapel Manor, its newest community in Zephyrhills, Florida.

KB Home announces the grand opening of Chapel Manor, its newest community in Zephyrhills, Florida.

維也納--(BUSINESS WIRE)--十二月 8, 2025--

(美國商業資訊)-- AOP Health持續推進其在骨髓增生性腫瘤(一類特殊且罕見的血液腫瘤)領域的臨床研發計畫。這家專注於罕見疾病治療的公司,於2025年在美國佛羅里達州奧蘭多舉行的第67 屆美國血液學會(American Society of Hematology, ASH)年會上,發布了兩項科學研究成果,將為治療策略帶來新的見解。

本新聞稿包含多媒體資訊。完整新聞稿請見此: https://www.businesswire.com/news/home/20251207103807/zh-HK/

ROP-ET與BESREMI PASS

其中一項臨床研究ROP-ET,探討Ropeginterferon alfa-2b在 原發性血小板增多症 (ET)患者中的使用情況。ET是一種由於體內產生的血小板過多而引發的疾病。此試驗為一項前瞻性、多中心、單組第III期臨床研究,評估Ropeginterferon alfa-2b在無法接受現有細胞減量治療 1 的ET患者中的安全性與療效。

另一項研究為BESREMI-PASS研究,旨在觀察該藥物在 原發性紅血球增多症 (PV)患者日常臨床治療中的效果。PV是一種罕見的血液幹細胞癌症,起源於骨髓造血幹細胞,會導致紅血球、白血球及血小板長期異常增多。

致力於滿足尚未被滿足的醫療需求

上述兩項研究,皆為Ropeginterferon α-2b在協助慢性血癌患者治療方面提供了新的見解。

AOP Health執行長Martin Steinhart總結道: 「AOP Health創立的初衷,正是為了回應罕見疾病領域中尚未被滿足的患者需求。我們對研發的持續投入,正體現了這項承諾,並帶來了新的研究成果。我們很榮幸能在ASH年會上,與全球科學界分享這些發現。」

關於Ropeginterferon alfa-2b

Ropeginterferon alfa-2b為全球首個獲准用於治療真性紅血球增多症(MPN)的干擾素藥物。依據歐盟核准內容,該藥物可作為單一療法,用於治療未出現脾腫大症狀的成人真性紅血球增多症患者。

Ropeginterferon alfa-2b屬於長效單聚乙二醇化脯氨酸干擾素(ATC:L03AB15)。初始治療階段為每兩週給藥一次,待血液學指標穩定後,可延長至每四週給藥一次。藥品採用預充式注射筆設計,供患者進行皮下注射使用。

關於AOP Health

AOP Orphan Pharmaceuticals GmbH (「AOP Health」)為一家跨國企業集團,根植於奧地利,集團總部亦設於此。自1996年成立以來,AOP Health Group持續致力於開發創新治療方案,以回應尚未被滿足的醫療需求,重點聚焦於罕見疾病與重症醫學領域。作為整合式治療方案的國際先驅,AOP Health Group透過子公司、代表處及強大的合作夥伴網路,在全球多地開展業務。秉持「需求、科學、信任」的核心理念,AOP Health Group強調對科研的長期承諾,並重視與醫療專業人士及病友組織的合作,確保關鍵利害關係人的需求能貫穿於公司各項行動之中。(aop-health.com)

1 Kiladjian JJ、Marin FF、Al-Ali HK等。ROP-ET:一項評估Ropeginterferon α-2b在治療選擇有限之原發性血小板增多症患者中有效性與安全性的前瞻性第III期臨床試驗。《血液學年鑑》,2024年3月4日:1–2。

需求、科學、信任。(Needs. Science. Trust.)
AOP Orphan Pharmaceuticals GmbH
AOP Health Group成員

免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

請前往 businesswire.com 瀏覽源版本:https://www.businesswire.com/news/home/20251207103807/zh-HK/

CONTACT: 深入咨詢

DI Isolde Fally

Isolde.Fally@aop-health.com

+43-676-500 4048

KEYWORD: AUSTRIA EUROPE UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY GENERAL HEALTH HEALTH CLINICAL TRIALS

SOURCE: AOP Health

Copyright Business Wire 2025.

PUB: 12/08/2025 12:14 AM/DISC: 12/08/2025 12:15 AM

http://www.businesswire.com/news/home/20251207103807/zh

AOP Health執行長Martin Steinhart博士;圖片來源:AOP Health/Studio Koekart

AOP Health執行長Martin Steinhart博士;圖片來源:AOP Health/Studio Koekart

Recommended Articles